Designation of Vinflunine Ditartrate (Javlor) as an Orphan Drug - Pierre Fabre Australia

Overview

The Therapeutic Goods Act 1989, enacted by the Parliament of Australia, aims to regulate the provision of therapeutic goods in the country. It provides a framework for the control of therapeutic goods, ensuring their quality, safety, and efficacy. One of the notable gaps this legislation addresses is the need for specific provisions to support the development and availability of orphan drugs for rare diseases or conditions. In this context, the Therapeutic Goods Administration designated vinflunine ditartrate (JAVLOR) as an orphan drug on 21 January 2015. This action was taken under the authority of the Therapeutic Goods Regulations 1990, recognising the need for such medications to treat rare conditions, such as advanced or metastatic transitional cell carcinoma of the urothelial tract after failure of a prior platinum-containing regimen. The policy objective behind this designation is to encourage the development and availability of treatments for rare diseases, ultimately improving health outcomes for patients with limited therapeutic options.

Scope and Application

The Therapeutic Goods Act 1989 designates vinflunine ditartrate (JAVLOR) as an orphan drug for the treatment of adult patients with advanced or metastatic transitional cell carcinoma of the urothelial tract who have failed a prior platinum-containing regimen. This designation is made under the authority of the Therapeutic Goods Regulations 1990, specifically subregulation 16J(2), by Dr Anthony Gill, a Delegate of the Secretary, effective from 21 January 2015. The application of this legislation pertains to vinflunine ditartrate (JAVLOR) and is limited to its use as an injection for the specified medical condition. The sponsor of this therapeutic good is Pierre Fabre Australia, and this designation is confined to the Commonwealth jurisdiction, impacting the regulation and approval processes of therapeutic goods within Australia. There are no explicit exclusions or thresholds mentioned in this particular gazette; however, the broader application and regulation of therapeutic goods in Australia may be subject to further stipulations and conditions as outlined in the Therapeutic Goods Act and its associated regulations.

Key Provisions

The key operative sections of this legislation pertain to the designation of vinflunine ditartrate (JAVLOR) as an orphan drug under the Therapeutic Goods Act 1989 and the Therapeutic Goods Regulations 1990. Specifically, Section 16J of the Regulations provides the authority for the designation of an orphan drug, with the designation in this instance being executed under subregulation 16J(2) (sections 16J and 16J(2)). Vinflunine ditartrate (JAVLOR) has been designated for the treatment of adult patients suffering from advanced or metastatic transitional cell carcinoma of the urothelial tract who have previously failed treatment with a platinum-containing regimen. The dosage form designated for this treatment is an injection, and the sponsor of this therapeutic good is Pierre Fabre Australia. This Act and its subsequent designation impose several obligations and requirements on the parties involved. The Therapeutic Goods Administration (TGA) must ensure that the therapeutic good meets the necessary standards of quality, safety, and efficacy for the designated orphan drug indication. The sponsor, Pierre Fabre Australia, must provide evidence and data supporting the safety and efficacy of vinflunine ditartrate (JAVLOR) for the specified use. Furthermore, the sponsor must adhere to all regulatory requirements for the marketing and distribution of the therapeutic good within Australia. Breaching the provisions of the Therapeutic Goods Act 1989 or the Therapeutic Goods Regulations 1990 can lead to various civil and criminal consequences. For instance, supplying a therapeutic good that does not meet the required standards may result in penalties, including fines and imprisonment. Specifically, under Section 33 of the Therapeutic Goods Act 1989, a person who contravenes a provision of the Act, such as supplying a therapeutic good that does not comply with the necessary standards, may face a fine of up to $222,200 for an individual or $1,111,000 for a body corporate, as well as imprisonment for up to five years. Additionally, under Section 34, a person who is found guilty of an offence under the Act may also be subject to additional civil penalties, including court-ordered compensation to affected parties. In conclusion, this legislation designates vinflunine ditartrate (JAVLOR) as an orphan drug for a specific medical indication, placing obligations on the TGA and the sponsor to ensure compliance with quality, safety, and efficacy standards. Failure to comply with the Act or Regulations can lead to severe penalties, including substantial fines and imprisonment. These provisions are crucial in ensuring that therapeutic goods available in Australia meet the necessary standards to protect public health.